CELLULARLINE SPA (CELL.MI) Fundamental Analysis & Valuation

BIT:CELL • IT0005244618

Current stock price

2.38 EUR
-0.04 (-1.65%)
Last:

This CELL.MI fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

3

1. CELL.MI Profitability Analysis

1.1 Basic Checks

  • CELL had positive earnings in the past year.
  • CELL had a positive operating cash flow in the past year.
  • The reported net income has been mixed in the past 5 years: CELL reported negative net income in multiple years.
  • CELL had a positive operating cash flow in each of the past 5 years.
CELL.MI Yearly Net Income VS EBIT VS OCF VS FCFCELL.MI Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 20M -20M -40M -60M

1.2 Ratios

  • The Return On Assets of CELL (2.60%) is comparable to the rest of the industry.
  • Looking at the Return On Equity, with a value of 4.27%, CELL is in line with its industry, outperforming 55.88% of the companies in the same industry.
  • CELL has a Return On Invested Capital (4.42%) which is in line with its industry peers.
Industry RankSector Rank
ROA 2.6%
ROE 4.27%
ROIC 4.42%
ROA(3y)-10.28%
ROA(5y)-5.5%
ROE(3y)-16.94%
ROE(5y)-9.21%
ROIC(3y)N/A
ROIC(5y)N/A
CELL.MI Yearly ROA, ROE, ROICCELL.MI Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -20 -40

1.3 Margins

  • CELL has a Profit Margin of 3.44%. This is comparable to the rest of the industry: CELL outperforms 50.00% of its industry peers.
  • In the last couple of years the Profit Margin of CELL has declined.
  • CELL has a Operating Margin of 4.91%. This is comparable to the rest of the industry: CELL outperforms 52.94% of its industry peers.
  • In the last couple of years the Operating Margin of CELL has declined.
  • Looking at the Gross Margin, with a value of 40.07%, CELL is in line with its industry, outperforming 58.82% of the companies in the same industry.
  • In the last couple of years the Gross Margin of CELL has declined.
Industry RankSector Rank
OM 4.91%
PM (TTM) 3.44%
GM 40.07%
OM growth 3Y35.04%
OM growth 5Y-19.56%
PM growth 3YN/A
PM growth 5Y-23.32%
GM growth 3Y-2.78%
GM growth 5Y-2.73%
CELL.MI Yearly Profit, Operating, Gross MarginsCELL.MI Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 20 -20 40 -40 60

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

7

2. CELL.MI Health Analysis

2.1 Basic Checks

  • With a Return on Invested Capital (ROIC) below the Cost of Capital (WACC), CELL is destroying value.
  • Compared to 1 year ago, CELL has less shares outstanding
  • CELL has less shares outstanding than it did 5 years ago.
  • CELL has a better debt/assets ratio than last year.
CELL.MI Yearly Shares OutstandingCELL.MI Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 5M 10M 15M 20M
CELL.MI Yearly Total Debt VS Total AssetsCELL.MI Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 100M 200M 300M

2.2 Solvency

  • An Altman-Z score of 2.32 indicates that CELL is not a great score, but indicates only limited risk for bankruptcy at the moment.
  • CELL has a better Altman-Z score (2.32) than 64.71% of its industry peers.
  • The Debt to FCF ratio of CELL is 2.46, which is a good value as it means it would take CELL, 2.46 years of fcf income to pay off all of its debts.
  • With a decent Debt to FCF ratio value of 2.46, CELL is doing good in the industry, outperforming 73.53% of the companies in the same industry.
  • A Debt/Equity ratio of 0.13 indicates that CELL is not too dependend on debt financing.
  • The Debt to Equity ratio of CELL (0.13) is better than 82.35% of its industry peers.
Industry RankSector Rank
Debt/Equity 0.13
Debt/FCF 2.46
Altman-Z 2.32
ROIC/WACC0.47
WACC9.38%
CELL.MI Yearly LT Debt VS Equity VS FCFCELL.MI Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 50M 100M 150M 200M

2.3 Liquidity

  • CELL has a Current Ratio of 2.12. This indicates that CELL is financially healthy and has no problem in meeting its short term obligations.
  • CELL has a better Current ratio (2.12) than 76.47% of its industry peers.
  • A Quick Ratio of 1.33 indicates that CELL should not have too much problems paying its short term obligations.
  • With a decent Quick ratio value of 1.33, CELL is doing good in the industry, outperforming 67.65% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 2.12
Quick Ratio 1.33
CELL.MI Yearly Current Assets VS Current LiabilitesCELL.MI Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M 100M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

3

3. CELL.MI Growth Analysis

3.1 Past

  • The Earnings Per Share has grown by an impressive 60.78% over the past year.
  • CELL shows a very negative growth in Earnings Per Share. Measured over the last years, the EPS has been decreasing by -20.43% yearly.
  • Looking at the last year, CELL shows a small growth in Revenue. The Revenue has grown by 3.54% in the last year.
  • CELL shows a small growth in Revenue. Measured over the last years, the Revenue has been growing by 3.18% yearly.
EPS 1Y (TTM)60.78%
EPS 3YN/A
EPS 5Y-20.43%
EPS Q2Q%-4.76%
Revenue 1Y (TTM)3.54%
Revenue growth 3Y14.1%
Revenue growth 5Y3.18%
Sales Q2Q%-2.91%

3.2 Future

  • Based on estimates for the next years, CELL will show a small growth in Earnings Per Share. The EPS will grow by 2.47% on average per year.
  • CELL is expected to show a decrease in Revenue. In the coming years, the Revenue will decrease by -0.60% yearly.
EPS Next Y-15%
EPS Next 2Y2.47%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next Year-6.17%
Revenue Next 2Y-0.6%
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

  • When comparing the EPS growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
  • The Revenue growth rate is decreasing: in the next years the growth will be less than in the last years.
CELL.MI Yearly Revenue VS EstimatesCELL.MI Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2016 2018 2019 2020 2021 2022 2023 2024 2025 2026 50M 100M 150M
CELL.MI Yearly EPS VS EstimatesCELL.MI Yearly EPS VS EstimatesYearly EPS VS Estimates 2018 2019 2020 2021 2022 2023 2024 2025 2026 0.2 0.4 0.6 0.8 1

More info and screens

Find the best growth stocksShow best growing peers

7

4. CELL.MI Valuation Analysis

4.1 Price/Earnings Ratio

  • The Price/Earnings ratio is 9.15, which indicates a very decent valuation of CELL.
  • CELL's Price/Earnings ratio is rather cheap when compared to the industry. CELL is cheaper than 91.18% of the companies in the same industry.
  • CELL is valuated cheaply when we compare the Price/Earnings ratio to 25.70, which is the current average of the S&P500 Index.
  • CELL is valuated cheaply with a Price/Forward Earnings ratio of 5.56.
  • Compared to the rest of the industry, the Price/Forward Earnings ratio of CELL indicates a rather cheap valuation: CELL is cheaper than 94.12% of the companies listed in the same industry.
  • CELL's Price/Forward Earnings ratio indicates a rather cheap valuation when compared to the S&P500 average which is at 23.84.
Industry RankSector Rank
PE 9.15
Fwd PE 5.56
CELL.MI Price Earnings VS Forward Price EarningsCELL.MI Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 20 40 60 80 100

4.2 Price Multiples

  • Compared to the rest of the industry, the Enterprise Value to EBITDA ratio of CELL indicates a rather cheap valuation: CELL is cheaper than 97.06% of the companies listed in the same industry.
  • Based on the Price/Free Cash Flow ratio, CELL is valued cheaper than 100.00% of the companies in the same industry.
Industry RankSector Rank
P/FCF 3.49
EV/EBITDA 2.84
CELL.MI Per share dataCELL.MI EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 2 4 6

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y2.47%
EPS Next 3YN/A

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

6

5. CELL.MI Dividend Analysis

5.1 Amount

  • CELL has a Yearly Dividend Yield of 3.84%.
  • CELL's Dividend Yield is rather good when compared to the industry average which is at 0.92. CELL pays more dividend than 94.12% of the companies in the same industry.
  • CELL's Dividend Yield is rather good when compared to the S&P500 average which is at 1.82.
Industry RankSector Rank
Dividend Yield 3.84%

5.2 History

Dividend Growth(5Y)N/A
Div Incr Years0
Div Non Decr Years0

5.3 Sustainability

  • 34.37% of the earnings are spent on dividend by CELL. This is a low number and sustainable payout ratio.
DP34.37%
EPS Next 2Y2.47%
EPS Next 3YN/A
CELL.MI Yearly Income VS Free CF VS DividendCELL.MI Yearly Income VS Free CF VS DividendYearly Income VS Free CF VS Dividend 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 20M -20M -40M -60M
CELL.MI Dividend Payout.CELL.MI Dividend Payout, showing the Payout Ratio.CELL.MI Dividend Payout.PayoutRetained Earnings

More info and screens

Find the best dividend stocksShow peers with best dividend

CELL.MI Fundamentals: All Metrics, Ratios and Statistics

CELLULARLINE SPA

BIT:CELL (3/13/2026, 4:58:59 PM)

2.38

-0.04 (-1.65%)

Chartmill FA Rating
GICS IndustryGroupTechnology Hardware & Equipment
GICS IndustryTechnology Hardware, Storage & Peripherals
Earnings (Last)03-09
Earnings (Next)05-05
Inst Owners4.94%
Inst Owner ChangeN/A
Ins Owners19.57%
Ins Owner ChangeN/A
Market Cap52.05M
Revenue(TTM)164.26M
Net Income(TTM)5.65M
Analysts82.86
Price Target4.18 (75.63%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield 3.84%
Yearly Dividend0.08
Dividend Growth(5Y)N/A
DP34.37%
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)0%
EPS NY rev (3m)0%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)0%
Revenue NY rev (3m)0%
Valuation
Industry RankSector Rank
PE 9.15
Fwd PE 5.56
P/S 0.32
P/FCF 3.49
P/OCF 2.56
P/B 0.39
P/tB 0.96
EV/EBITDA 2.84
EPS(TTM)0.26
EY10.92%
EPS(NY)0.43
Fwd EY18%
FCF(TTM)0.68
FCFY28.66%
OCF(TTM)0.93
OCFY39%
SpS7.51
BVpS6.05
TBVpS2.49
PEG (NY)N/A
PEG (5Y)N/A
Graham Number5.95
Profitability
Industry RankSector Rank
ROA 2.6%
ROE 4.27%
ROCE 5.04%
ROIC 4.42%
ROICexc 5.33%
ROICexgc 12.93%
OM 4.91%
PM (TTM) 3.44%
GM 40.07%
FCFM 9.08%
ROA(3y)-10.28%
ROA(5y)-5.5%
ROE(3y)-16.94%
ROE(5y)-9.21%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3Y46.34%
ROICexgc growth 5Y-17.53%
ROICexc growth 3Y77.77%
ROICexc growth 5Y-8.95%
OM growth 3Y35.04%
OM growth 5Y-19.56%
PM growth 3YN/A
PM growth 5Y-23.32%
GM growth 3Y-2.78%
GM growth 5Y-2.73%
F-Score4
Asset Turnover0.76
Health
Industry RankSector Rank
Debt/Equity 0.13
Debt/FCF 2.46
Debt/EBITDA 0.81
Cap/Depr 39.19%
Cap/Sales 3.28%
Interest Coverage 2.77
Cash Conversion 93.13%
Profit Quality 264.18%
Current Ratio 2.12
Quick Ratio 1.33
Altman-Z 2.32
F-Score4
WACC9.38%
ROIC/WACC0.47
Cap/Depr(3y)26.8%
Cap/Depr(5y)35.01%
Cap/Sales(3y)3.22%
Cap/Sales(5y)4.78%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)60.78%
EPS 3YN/A
EPS 5Y-20.43%
EPS Q2Q%-4.76%
EPS Next Y-15%
EPS Next 2Y2.47%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)3.54%
Revenue growth 3Y14.1%
Revenue growth 5Y3.18%
Sales Q2Q%-2.91%
Revenue Next Year-6.17%
Revenue Next 2Y-0.6%
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y59.25%
EBIT growth 3Y54.08%
EBIT growth 5Y-17%
EBIT Next Year25.99%
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y1050.19%
FCF growth 3Y4.84%
FCF growth 5Y6.28%
OCF growth 1Y730.91%
OCF growth 3Y4.12%
OCF growth 5Y1.2%

CELLULARLINE SPA / CELL.MI Fundamental Analysis FAQ

What is the ChartMill fundamental rating of CELLULARLINE SPA (CELL.MI) stock?

ChartMill assigns a fundamental rating of 5 / 10 to CELL.MI.


What is the valuation status for CELL stock?

ChartMill assigns a valuation rating of 7 / 10 to CELLULARLINE SPA (CELL.MI). This can be considered as Undervalued.


What is the profitability of CELL stock?

CELLULARLINE SPA (CELL.MI) has a profitability rating of 3 / 10.


What are the PE and PB ratios of CELLULARLINE SPA (CELL.MI) stock?

The Price/Earnings (PE) ratio for CELLULARLINE SPA (CELL.MI) is 9.15 and the Price/Book (PB) ratio is 0.39.


Can you provide the dividend sustainability for CELL stock?

The dividend rating of CELLULARLINE SPA (CELL.MI) is 6 / 10 and the dividend payout ratio is 34.37%.